CG Oncology (CGON) Net Cash Flow (2023 - 2026)

CG Oncology (CGON) has 4 years of Net Cash Flow data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 100.58% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$7.7 million (up 78.53% YoY), and the FY2025 full-year result was -$224.6 million, down 190.26% from the prior year.
• Net Cash Flow for Q1 2026 stood at $1.3 million, up from -$12.7 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $213.7 million in Q4 2024 and bottomed at -$215.6 million in Q1 2025.
• The 4-year median for Net Cash Flow is -$2.0 million (2023), against an average of -$4.2 million.
• The widest annual swing landed in 2024, when Net Cash Flow soared 10745.59%; it then slumped 411.55% in 2025.
• A 4-year view of Net Cash Flow shows it stood at -$2.0 million in 2023, then jumped by 10745.59% to $213.7 million in 2024, then sank by 105.94% to -$12.7 million in 2025, then jumped by 109.88% to $1.3 million in 2026.
• The last three Net Cash Flow figures came in at $1.3 million (Q1 2026), -$12.7 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.

Peer Comparison